PT  - JOURNAL ARTICLE
AU  - Yan, Lily D
AU  - Pierre, Jean Lookens
AU  - Rouzier, Vanessa
AU  - Théard, Michel
AU  - Apollon, Alexandra
AU  - St-Preux, Stephano
AU  - Kingery, Justin R
AU  - Jamerson, Kenneth A
AU  - Deschamps, Marie
AU  - Pape, Jean W
AU  - Safford, Monika M
AU  - McNairy, Margaret L
TI  - Cardiovascular Disease Risk Prediction Models in Haiti: Implications for Primary Prevention in Low-Middle Income Countries
AID  - 10.1101/2021.07.29.21261344
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.29.21261344
4099  - http://medrxiv.org/content/early/2021/08/01/2021.07.29.21261344.short
4100  - http://medrxiv.org/content/early/2021/08/01/2021.07.29.21261344.full
AB  - Background Cardiovascular diseases (CVD) are rapidly increasing in low-middle income countries (LMICs). Accurate risk assessment is essential to reduce premature CVD by targeting primary prevention and risk factor treatment among high-risk groups. Available CVD risk prediction models are built on predominantly Caucasian, high-income country populations, and have not been evaluated in LMIC populations.Objective To compare the predicted 10-year risk of CVD and identify high-risk groups for targeted prevention and treatment in Haiti.Methods We used cross-sectional data within the Haiti CVD Cohort Study, including 653 adults ≥ 40 years without known history of CVD and with complete data. Six CVD risk prediction models were compared: pooled cohort equations (PCE), adjusted PCE with updated cohorts, Framingham CVD Lipids, Framingham CVD Body Mass Index (BMI), WHO Lipids, and WHO BMI. Risk factors were measured during clinical exams. Primary outcome was continuous and categorical predicted 10-year CVD risk. Secondary outcome was statin eligibility.Results Seventy percent were female, 65.5% lived on a daily income of ≤1 USD, 57.0% had hypertension, 14.5% had hypercholesterolemia, 9.3% had diabetes mellitus, 5.5% were current smokers, and 2.0% had HIV. Predicted 10-year CVD risk ranged from 3.9% in adjusted PCE (IQR 1.7-8.4) to 9.8% in Framingham-BMI (IQR 5.0-17.8), and Spearman rank correlation coefficients ranged from 0.87 to 0.98. The percent of the cohort categorized as high risk using the uniform threshold of 10-year CVD risk ≥ 7.5% ranged from 28.8% in the adjusted PCE model to 62.0% in the Framingham-BMI model (χ2 = 331, p value < 0.001). Statin eligibility also varied widely.Conclusions In the Haiti CVD Cohort, there was substantial variation in the proportion identified as high-risk and statin eligible using existing models, leading to very different treatment recommendations and public health implications depending on which prediction model is chosen. There is a need to design and validate CVD risk prediction tools for low-middle income countries that include locally relevant risk factors.Trial registration clinicaltrials.gov NCT03892265Competing Interest StatementJLP, VR, JWP, MLM report a grant from NHLBI R01HL143788. The remaining authors declare they have no conflicts of interest.Clinical TrialNCT03892265Clinical Protocols https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603639/ Funding StatementFunding for this study comes from the National Heart, Lung, and Blood Institute, grant number R01HL143788. The funders had no role in the study design or execution of this protocol.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by institutional review boards at Weill Cornell Medicine and Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO) (record number 1803019037), with written participant consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResearchers who provide a methodologically sound proposal may have access to a subset of deidentified participant data, with specific variables based on the proposal. Proposals should be directed to the principal investigator at mam9365@med.cornell.edu. To gain access, data requestors will need to sign a data access agreement. Data are available following publications through 3 years after publication and will be provided directly from the PI.aPCEadjusted pooled cohort equationsBMIbody mass indexBPblood pressureCVDcardiovascular diseaseDBPdiastolic blood pressureGHESKIOGroupe Haïtien d’Etude du Sarcome de Kaposi et des Infections Opportunistes clinicsIQRinterquartile rangeLMIClow middle income countriesPCEpooled cohort equationsSBPsystolic blood pressureSCOREsystematic coronary risk evaluation modelWHOWorld Health Organization